Evidence map›Paper›PMID 36399908›Full record

ArticleJournal of pharmaceutical and biomedical analysis2023

Quantitative assessment of the in-vitro binding kinetics of antisickling aromatic aldehydes with hemoglobin A: A universal HPLC-UV/Vis method to quantitate Schiff-base adduct formation.

Xiaomeng Xu, Mohini S Ghatge, Boshi Huang, Ahmed Alghamdi, Huiqun Wang, B Daniel Pierce, Osheiza Abdulmalik, Yan Zhang, Martin K Safo, Jürgen Venitz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Xiaomeng XuDivision of Cardiometabolic and Endocrine Pharmacology, Office of Clinical Pharmacology, Center of Drug Evaluation and Research, US FDA, Silver spring, MD 20993, USA; Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Mohini S GhatgeDepartment of Medicinal Chemistry and The Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Boshi HuangDepartment of Medicinal Chemistry and The Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Ahmed AlghamdiDepartment of Medicinal Chemistry and The Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Huiqun WangDepartment of Medicinal Chemistry and The Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
B Daniel PierceDepartment of Biology, University of Richmond, Richmond, VA 23173, USA.
Osheiza AbdulmalikDivision of Hematology, The Children's Hospital of Philadelphia, PA 19104, USA.
Yan ZhangDepartment of Medicinal Chemistry and The Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Martin K SafoDepartment of Medicinal Chemistry and The Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: msafo@vcu.edu.
Jürgen VenitzDepartment of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Virginia Commonwealth University · USChildren's Hospital of Philadelphia · USUnited States Food and Drug Administration · USUniversity of Richmond · US

Funding

Hemoglobin Modifiers for Sickle Cell Disease TherapyR01MD009124 · NIMHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAFO, MARTIN K · 2014 to 2018
$2.1M
Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease TherapyR61HL156158 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI ABDULMALIK, OSHEIZA Y, SAFO, MARTIN K · 2021 to 2022
$1.1M
X-ray Crystallographic Data Collection SystemS10OD021756 · OD · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAFO, MARTIN K · 2017 to 2017
$600k
Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease TherapyR33HL156158 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI ABDULMALIK, OSHEIZA Y, SAFO, MARTIN K · 2023 to 2023
$572k
NHLBI NIH HHS R33 HL156158NHLBI NIH HHS R61 HL156158NIH HHS S10 OD021756NIMHD NIH HHS R01 MD009124
6 · The paper itself

Abstract

Aromatic aldehydes act as allosteric effectors of hemoglobin (AEH), forming Schiff-base adducts with the protein to increase its oxygen (O

Indexed as

AldehydesHemoglobin AChromatography, High Pressure LiquidHemoglobin, SickleOxygenSchiff BasesAldehydesHemoglobin Ahemoglobin ASHemoglobin, SickleOxygenSchiff BasesAllosteric effectors of hemoglobinAntisicklingBinding affinity and kineticsHemoglobinSickle cell diseaseUniversal method

Identifiers

PMID36399908
PMCPMC9701171
OpenAlexW4309507321

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.